Zhenghe Wang

List of Publications by Year
in descending order

50 papers	5,701 citations	257450 24 h-index	214800 47 g-index
53 all docs	53 docs citations	53 times ranked	9853 citing authors

#	Article	IF	Citations
1	Nuclear translocation of p85Î² promotes tumorigenesis of PIK3CA helical domain mutant cancer. Nature Communications, 2022, 13, 1974.	12.8	13
2	Deep proteomic analysis of Dnmt1 mutant/hypomorphic colorectal cancer cells reveals dysregulation of epithelialâ€“mesenchymal transition and subcellular re-localization of Beta-Catenin. Epigenetics, 2020, 15, 107-121.	2.7	4
3	Noninvasive assessment and therapeutic monitoring of drug-resistant colorectal cancer by MR molecular imaging of extradomain-B fibronectin. Theranostics, 2020, 10, 11127-11143.	10.0	14
4	5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA-Mutant Colorectal Cancers. Cancer Research, 2020, 80, 4815-4827.	0.9	49
5	A facile and sensitive method of quantifying glutaminase binding to its inhibitor CB-839 in tissues. Journal of Genetics and Genomics, 2020, 47, 389-395.	3.9	4
6	Mutations in TP53, ZNF750, and RB1 typify ocular sebaceous carcinoma. Journal of Genetics and Genomics, 2019, 46, 315-318.	3.9	5
7	Colorectal cancers utilize glutamine as an anaplerotic substrate of the TCA cycle in vivo. Scientific Reports, 2019, 9, 19180.	3.3	37
8	Research highlights from ACACR members. Genes and Diseases, 2018, 5, 301.	3.4	0
9	Multiproteomic and Transcriptomic Analysis of Oncogenic Î²-Catenin Molecular Networks. Journal of Proteome Research, 2018, 17, 2216-2225.	3.7	6
10	Quantitative Analysis of Alternative Pre-mRNA Splicing in Mouse Brain Sections Using RNA In Situ Hybridization Assay. Journal of Visualized Experiments, 2018, , .	0.3	6
11	Phase I clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumors.. Journal of Clinical Oncology, 2018, 36, 2562-2562.	1.6	9
12	Novel all-hydrocarbon stapled p110Î±[E545K] peptides as blockers of the oncogenic p110Î±[E545K]-IRS1 interaction. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5446-5449.	2.2	7
13	Regulation of paxillin-p130-PI3K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis. Oncotarget, 2017, 8, 48782-48793.	1.8	28
14	Inhibition of intracellular lipolysis promotes human cancer cell adaptation to hypoxia. ELife, 2017, 6, .	6.0	104
15	Adverse Clinical Outcome Associated With Mutations That Typify African American Colorectal Cancers. Journal of the National Cancer Institute, 2016, 108, djw164.	6.3	7
16	Targeting glutamine metabolism in PIK3CA mutant colorectal cancers. Genes and Diseases, 2016, 3, 241-243.	3.4	13
17	Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. Nature Communications, 2016, 7, 11971.	12.8	203
18	STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma. Cancer Prevention Research, 2016, 9, 657-663.	1.5	12

#	Article	IF	Citations
19	Abstract B03: Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancers. , 2016, , .		0
20	A Protein Interaction between Î²-Catenin and Dnmt1 Regulates Wnt Signaling and DNA Methylation in Colorectal Cancer Cells. Molecular Cancer Research, 2015, 13, 969-981.	3.4	44
21	Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. Science, 2015, 348, aaa2340.	12.6	220
22	Novel thiourea-based sirtuin inhibitory warheads. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3319-3324.	2.2	36
23	DNMT1-associated long non-coding RNAs regulate global gene expression and DNA methylation in colon cancer. Human Molecular Genetics, 2015, 24, 6240-6253.	2.9	167
24	How do oncoprotein mutations rewire proteinâ€“protein interaction networks?. Expert Review of Proteomics, 2015, 12, 449-455.	3.0	18
25	Cancer driver candidate genes AVL9, DENND5A and NUPL1 contribute to MDCK cystogenesis. Oncoscience, 2014, 1, 854-865.	2.2	34
26	Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1114-1119.	7.1	86
27	CtIP is required for DNA damage-dependent induction ofP21. Cell Cycle, 2014, 13, 90-95.	2.6	8
28	Targeting the Proteinâ€“Protein Interaction between IRS1 and Mutant p110Î± for Cancer Therapy. Toxicologic Pathology, 2014, 42, 140-147.	1.8	11
29	PTPRT Regulates High-Fat Diet-Induced Obesity and Insulin Resistance. PLoS ONE, 2014, 9, e100783.	2.5	26
30	Gain of Interaction with IRS1 by p110Î±-Helical Domain Mutants Is Crucial for Their Oncogenic Functions. Cancer Cell, 2013, 23, 583-593.	16.8	85
31	Identifying Novel Protein Complexes in Cancer Cells Using Epitope-Tagging of Endogenous Human Genes and Affinity-Purification Mass Spectrometry. Journal of Proteome Research, 2012, 11, 5630-5641.	3.7	20
32	Potent sirtuin inhibition bestowed by l-2-amino-7-carboxamidoheptanoic acid (l-ACAH), a NÎµ-acetyl-lysine analog. MedChemComm, 2011, 2, 291.	3.4	19
33	A mechanism-based potent sirtuin inhibitor containing NÎµ-thiocarbamoyl-lysine (TuAcK). Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4753-4757.	2.2	22
34	Tumour suppressor function of protein tyrosine phosphatase receptor-T. Bioscience Reports, 2011, 31, 303-307.	2.4	31
35	Characterization of the Adhesive Properties of the Type IIb Subfamily Receptor Protein Tyrosine Phosphatases. Cell Communication and Adhesion, 2010, 17, 34-47.	1.0	24
36	Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2592-2597.	7.1	69

#	Article	IF	Citations
37	DNMT1 Stability Is Regulated by Proteins Coordinating Deubiquitination and Acetylation-Driven Ubiquitination. Science Signaling, 2010, 3, ra80.	3.6	278
38	Discovery of potent, proteolytically stable, and cell permeable human sirtuin peptidomimetic inhibitors containing NÎµ-thioacetyl-lysine. MedChemComm, 2010, 1, 233.	3.4	21
39	Cancer-Derived Mutations in the Fibronectin III Repeats of PTPRT/PTPÏ•Inhibit Cell-Cell Aggregation. Cell Communication and Adhesion, 2010, 16, 146-153.	1.0	25
40	Hypoxia-mediated regulation of Cdc25A phosphatase by p21 and miR-21. Cell Cycle, 2009, 8, 3157-3164.	2.6	39
41	Epitope Tagging of Endogenous Proteins for Genome-Wide Chromatin Immunoprecipitation Analysis. Methods in Molecular Biology, 2009, 567, 87-98.	0.9	12
42	Epitope tagging of endogenous proteins for genome-wide ChIP-chip studies. Nature Methods, 2008, 5, 163-165.	19.0	92
43	Tumor-Derived Extracellular Mutations of PTPRT/PTPÏ•Are Defective in Cell Adhesion. Molecular Cancer Research, 2008, 6, 1106-1113.	3.4	44
44	Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers. Science, 2004, 304, 1164-1166.	12.6	498
45	From spindle checkpoint to cancer. Nature Genetics, 2004, 36, 1144-1145.	21.4	28
46	High Frequency of Mutations of the PIK3CA Gene in Human Cancers. Science, 2004, 304, 554-554.	12.6	3,048
47	Phosphorylation of beta-catenin at S33, S37, or T41 can occur in the absence of phosphorylation at T45 in colon cancer cells. Cancer Research, 2003, 63, 5234-5.	0.9	47
48	Targeted inactivation of CTNNB1 reveals unexpected effects of Â-catenin mutation. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8265-8270.	7.1	120
49	Replication-Related Activities Establish Cohesion Between Sister Chromatids. Cell Biochemistry and Biophysics, 2001, 35, 289-301.	1.8	8
50	Targeting glutamine metabolism inPIK3CAmutant colorectal cancers. Molecular and Cellular Oncology, 0, , 00-00.	0.7	0